Oslo, Norway, April 20, 2023 - The Board of Directors of Nykode Therapeutics ASA
(OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the
discovery and development of novel immunotherapies, hereby calls for the Annual
General Meeting to be held at meeting room FORUM - Building H, Floor 0 in
Gaustadalléen 21, Oslo, Norway at 10:00 CET on May 11, 2023.
All documents regarding the Annual General Meeting are available at the
For further information, please see the Company's website or contact CFO Harald
Gurvin. Please see below for contact details.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode's modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which have been shown to induce
broad, strong and long-lasting antigen specific immune responses which
correlates with clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive safety and efficacy results from its Phase 2 trial for the
treatment of cervical cancer